Register for Zoom In on Dementia & Alzheimer’s: Clinical Research
Register for Zoom In on Dementia & Alzheimer’s: Clinical Research
Register to join our free virtual program and engage in a live conversation with experts in the field.
TOPIC
Trontinemab: A New Brain-Penetrant Alzheimer’s Therapy
DATE
Thursday, August 27, 2026
TIME
1 pm ET (please adjust for your time zone)
SPEAKER(S)
Gil Rabinovici, MD
Join renowned Alzheimer’s researcher Dr. Gil Rabinovici for an in-depth discussion of trontinemab, an investigational next-generation anti-amyloid therapy being studied for early Alzheimer’s disease. Learn about the innovative Brainshuttle™ technology designed to improve drug delivery to the brain, the TRONTIER 1 and 2 clinical trials, the TRAVELLER pre-screening study, and the ambitious PrevenTRON prevention study exploring whether early treatment may help stop or prevent symptoms altogether in people at high risk for Alzheimer’s disease.
Watch Past Episodes
Lewy Body, Alzheimer’s & Mixed Dementias Explained
Leading neurologist Dr. James E. Galvin explains how to identify early warning signs, distinguish Lewy body dementia from Alzheimer’s disease, and explore current and emerging treatment options.
Agitation in Alzheimer’s Dementia
Dr. Brent Forester explains what causes agitation, how it may appear in different forms, and the latest approaches for managing symptoms—including non-drug strategies and newly approved treatments.
Stroke, Vascular Dementia, Alzheimer’s: What’s the Difference?
Dr. Jason Hinman of UCLA explains how disrupted blood flow to the brain can lead to cognitive decline, how vascular dementia differs from (and often overlaps with) Alzheimer’s disease, and what the latest research means for prevention and treatment.
Therapeutic TV for Alzheimer’s: What the Research Shows
Allyson Schrier shares how research following her experience caring for her husband with dementia led her to create a streaming service designed to calm, engage, and support people living with memory loss.
The SPRING Trial: Targeting Gum Bacteria in Alzheimer’s
Dr. Michael J. Detke of Lighthouse Pharma explains the SPRING clinical trial and how the investigational oral drug LHP588 is being studied to reduce bacteria-related brain damage.
Is It Alzheimer’s? Recognizing Early Signs & Symptoms
Behavioral neurologist Dr. Sharon Cohen explains the early signs and symptoms of Alzheimer’s disease, medical conditions that can mimic dementia, and how to start a conversation with your doctor.
Alzheimer’s Clinical Trials 2026: An Insider’s Look with Dr. Jeffrey Cummings
Join Dr. Jeffrey Cummings as he shares an insider’s overview of the evolving Alzheimer’s treatment development pipeline.
Understanding Your APOE Status: Genetics and Alzheimer’s Risk
About 25% of people carry one copy of the APOE4 gene, the strongest genetic risk factor for developing Alzheimer’s. Dr. Eric M. Reiman explains what genetic testing can—and cannot—tell you, including why APOE4 signals increased risk but does not mean a definite Alzheimer’s diagnosis.
Leqembi and Kisunla: Your Questions Answered
A leading neurologist answers your most common questions about what Leqembi and Kisunla can realistically do, including effectiveness, safety, eligibility, infusion logistics, cost, and access.
Zoom In on Dementia & Alzheimer’s is supported in part through sponsorships from:
